Mattias Lorentzon
Sahlgrenska University Hospital Mölndal, Västra Götalandsregionen and University of Gothenburg · Sahlgrenska University Hospital, Västra Götalandsregionen · Sahlgrenska University Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mattias Lorentzon as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:58 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT07772609 · Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMDSahlgrenska University Hospital · not yet recruiting · Osteoporosis in Post-menopausal Women · principal investigator
- N/ANCT06603545 · The Effect of Digital Education for Osteoporosis Patients on Fracture Risk and Related Health Outcomes.Sahlgrenska University Hospital · recruiting · Osteoporosis, Accidental Falls, Fractures, Bone · principal investigator
- N/ANCT04767711 · Prevention of Glucocorticoid Induced Impairment of Bone MetabolismSahlgrenska University Hospital · completed · Bone Loss · principal investigator
- N/ANCT04755686 · Effects of Fast-tracking Geriatric Hip Fracture PatientsSahlgrenska University Hospital · withdrawn · Hip Fracture · principal investigator
- N/ANCT04169789 · Prevention of Early Postmenopausal Bone Loss With Lactobacillus ReuteriSahlgrenska University Hospital · completed · Postmenopausal Osteoporosis · principal investigator
- N/ANCT02422082 · The Effect of Lactobacillus Reuteri ATCC PTA 6475 on Volumetric Bone Mineral Density in Patients With OsteopeniaSahlgrenska University Hospital · completed · Osteopenia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:58 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- 1,184 citationsRCR 53.0
- Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial.J Intern Med · 2018264 citationsRCR 11.8
- Type 2 Diabetes Mellitus Is Associated With Better Bone Microarchitecture But Lower Bone Material Strength and Poorer Physical Function in Elderly Women: A Population-Based Study.J Bone Miner Res · 2017177 citationsRCR 8.9
- Low-Level Cadmium Exposure Is Associated With Decreased Bone Mineral Density and Increased Risk of Incident Fractures in Elderly Men: The MrOS Sweden Study.J Bone Miner Res · 2016104 citationsRCR 5.8
- One-year supplementation with Lactobacillus reuteri ATCC PTA 6475 counteracts a degradation of gut microbiota in older women with low bone mineral density.NPJ Biofilms Microbiomes · 202267 citationsRCR 5.9
- A High Amount of Local Adipose Tissue Is Associated With High Cortical Porosity and Low Bone Material Strength in Older Women.J Bone Miner Res · 201661 citationsRCR 3.0
- A 6-year exercise program improves skeletal traits without affecting fracture risk: a prospective controlled study in 2621 children.J Bone Miner Res · 201446 citationsRCR 2.3
- High-Impact Mechanical Loading Increases Bone Material Strength in Postmenopausal Women-A 3-Month Intervention Study.J Bone Miner Res · 201845 citationsRCR 2.6
- Limosilactobacillus reuteri 6475 and Prevention of Early Postmenopausal Bone Loss: A Randomized Clinical Trial.JAMA Netw Open · 202429 citationsRCR 4.9
- Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability-results from the Women's Health Initiative hormone therapy trials.Osteoporos Int · 202226 citationsRCR 2.5